Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2001

View Archived Issues

Synthetic peptide-based treatment for MS completes phase II trial in Canada

Tracleer NDA approvable, says FDA

Pivotal trial to begin soon for inhalable therapy for hereditary emphysema

Collagenase product for Dupuytren's disease heads for pivotal trials

Orion drops development of gel formulation of progestin

XTL continues to build strong infectious disease therapeutic pipeline

M-40403 improves diabetic vascular dysfunction and nerve damage

Levodopa with physiotherapy may improve motor recovery in stroke

Novel class of small nonpeptidyl compounds selectively inhibit malarial plasmepsins

Elastase inhibitors such as elafin may have clinical utility in intimal hyperplasia

Abbott presents new research findings in the area of protein farnesyltransferase inhibitors

New chemical series from American Cyanamid inhibits TACE and MMPs

Inhibitors of uPA binding and use as antitumor agents discussed by Roche

Pfizer scientists identify a series of CCR1 antagonists

Use of metabotropic glutamate receptor potentiators discussed by Lilly

Ortho-McNeil reports substituted amino acids that inhibit neutral sphingomyelinase activity

Animal studies support development of pyridoxamine for diabetic complications

Bradykinin B2 receptor modulators described in patent by Neurogen group

Tumor-imaging agents with selective affinity for vitronectin receptors

Inhibitex enters into partnership with Wyeth Lederle Vaccines

Negative results obtained in phase II GPG study

Broad development program under way for siplizumab

Enrollment of patients completed for phase III INS-365 Ophthalmic clinical program

FDA grants priority review status to etanercept for treatment of psoriatic arthritis

Optimization of anti-IL-9 antibody initiated

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026